[Parkinson's disease--new horizons].
New information about the pathology and genetics of Parkinson's disease opens up new possibilities for treatment. A key role is played by a pathologically folded protein, the distribution of which in the brain permits new conclusions about the stage of the disease. Gene mutations in affected families provide further clues as to the pathological process. In addition to symptom control, future treatment strategies will be aimed in particular at slowing down the underlying pathological process, and will therefore go in the direction of neuroprotection and neurorestoration. Dopamine agonists that can slow cell degeneration are already the first-line treatment in patients under 70 years of age.
Bötzel
K
K
Neurologische Klinik der Ludwig-Maximilians-Universität München, Klinikum Grosshadern. Kai.Boetzel@med.uni-muenchen.de
D000368:Aged; D003704:Dementia / Q000209:etiology / Q000517:prevention & control; D018491:Dopamine Agonists / Q000627:therapeutic use*; D015316:Genetic Therapy; D006801:Humans; D009474:Neurons / Q000473:pathology; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D000857:Olfaction Disorders / Q000209:etiology / Q000517:prevention & control; D010300:Parkinson Disease / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D013378:Substantia Nigra / Q000473:pathology
D018491:Dopamine Agonists; D018696:Neuroprotective Agents